Physician profile

Sun Duck Kwon

Physical Medicine & Rehabilitation · Norfolk, VA

NPI 1528383122

$817.23

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$542.40

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $196.41 2021-2024
Collegium Pharmaceutical, INC. $148.67 2021-2022
Pfizer INC. $121.86 2023
Bioventus LLC $84.25 2023-2024 Durolane, Durolane
Merz Pharmaceuticals, LLC $72.67 2023 Xeomin
Lundbeck LLC $61.81 2022-2023 Vyepti
Averitas Pharma INC. $55.36 2023 Qutenza
Nevro Corp. $39.82 2023 Senza
Abbott Laboratories $24.23 2023 Proclaim
Kowa Pharmaceuticals America, INC. $12.15 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sun Duck Kwon

$817.23

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/805250/sun-duck-kwon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.